Cancer. Silencing a metabolic oncogene

Science. 2013 May 3;340(6132):558-9. doi: 10.1126/science.1238523.

Abstract

Small molecules inhibit a mutant enzyme confined to tumors, supporting therapeutic approaches that can reprogram metabolism in cancer.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Animals
  • Benzeneacetamides / pharmacology*
  • Cell Differentiation*
  • Cell Transformation, Neoplastic / metabolism*
  • Enzyme Inhibitors / pharmacology*
  • Glioma / enzymology*
  • Glioma / pathology*
  • Glutarates / metabolism*
  • Hematopoiesis / drug effects*
  • Humans
  • Imidazoles / pharmacology*
  • Isocitrate Dehydrogenase / antagonists & inhibitors
  • Isocitrate Dehydrogenase / genetics
  • Isocitrate Dehydrogenase / metabolism*
  • Leukemia / enzymology*
  • Leukemia, Myeloid, Acute / enzymology*
  • Phenylurea Compounds / pharmacology*
  • Procollagen-Proline Dioxygenase / antagonists & inhibitors*
  • Sulfonamides / pharmacology*

Substances

  • AGI-5198
  • AGI-6780
  • Benzeneacetamides
  • Enzyme Inhibitors
  • Glutarates
  • Imidazoles
  • Phenylurea Compounds
  • Sulfonamides
  • IDH2 protein, human
  • Isocitrate Dehydrogenase
  • IDH1 protein, human
  • Procollagen-Proline Dioxygenase